Title: Yoga Effect on Quality-of-Life Study Among Patients with Idiopathic Pulmonary Fibrosis (YES-IPF)

Authors and affiliation: Suha Kadura[1], Soumik Purkayastha[2,6], Josh Benditt[1], Amit Anand[3], Bridget Collins[1], Miguele De Quadros[4], Mafara Hobson[4], MJ Biswas[4], Lawrence Ho[1], Cathie Spino[5], Ganesh Raghu*[1]

1- Division of Pulmonary, Critical Care and Sleep Medicine, Center for Interstitial Lung Diseases, Department of Medicine, University of Washington, Seattle, WA, USA

2- Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA.

3- Division of Pulmonary, Critical Care and Sleep Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.

4- Independent certified yoga instructors

5- Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA.

6- Center for Health Equity Research and Promotion, Pittsburgh, PA, USA

***Corresponding Author:** Ganesh Raghu, MD**,** University of Washington, Campus Box 356175, Seattle, WA 98195 USA**.** Email: graghu@uw.edu

Running title: Yoga Effect on Quality-of-Life in IPF Patients;

Descriptor Number: 9.23 Interstitial Lung Disease;

Total words: 3337

Abstract words: 247

Summary: We examine if the implementation of a modified yoga program improves patient-reported outcomes in patients with idiopathic pulmonary fibrosis. Our study reveals significant post-yoga improvements in the yoga group compared to the control group across

different patient-reported outcomes. Such outcomes are meaningful endpoints in patients with idiopathic pulmonary fibrosis and serve as a critical endpoint in related clinical trials.

Contributions:

1. *Suha Kadura:* Data gathering, interpretation of result, writing first draft, revised versions and collated inputs from all authors of the manuscript.
2. *Soumik Purkayastha:* Data analyses, interpretation of result, writing first draft, revised versions and collated inputs from all authors of the manuscript.
3. *Josh Benditt and Amit Anand:* Developed the protocol and study design for the modified yoga program /exercises used in the trial; reviewed the data analyzed, interpreted results.
4. *Josh Benditt, Amit Anand, Miguele De Quadros, Mafara Hobson, and MJ Biswas:* Certified yoga instructors for patients.
5. *Bridget Collins:* Enrolled consenting participants in the study, participated in study design, interpretation of results, reviewing manuscript and provided input.
6. *Lawrence Ho:* Enrolled and encouraged patients to participate in the trial.
7. *Cathie Spino:* Reviewed data analyses and interpretation, reviewed manuscript and provided input.
8. *Ganesh Raghu:* designed the trial and study protocol, enrolled consenting participants in the study, interpretation of results, supervised the conduct of trial and execution of the trial; manuscript writing.

All authors reviewed the drafts of manuscript, provided input, contributed to writing the manuscript and approved the final manuscript for submission.

Data availability statement: In accordance with our protocol registered at ClinicalTrials.gov (NCT02848625), individual participant data from this study will not be made available publicly. This approach was established to protect participant privacy and confidentiality as stated in our informed consent process. Summary data supporting the findings of this study are available within the article and its supplementary materials. Researchers interested in collaborative analyses may contact the corresponding author with specific research questions and proposed methodologies for consideration.

Funding Statement: No external funding or financial support was received for the conduct of this research, data analysis, manuscript preparation, or submission.

ABSTRACT

Rationale: Patients with idiopathic pulmonary fibrosis have poor health-related quality of life.

Objective: Determine whether a modified yoga program in patients with idiopathic pulmonary fibrosis improves quality of life compared to usual care.

Methods: Randomized controlled, non-blinded, pilot clinical trial lasting 12 weeks with 2 arms involving 63 adults with idiopathic pulmonary fibrosis. The yoga program-arm consisted of interventions such as seated postures, breathing and meditation exercises designed by authors for idiopathic pulmonary fibrosis patients. The control arm continued with usual standard of care. Analysis of covariance was performed; no multiplicity adjustments were made on account of this being a pilot study.

Measurements: The primary outcomes were week-12 scores in seven patient-reported instruments, each with sub-domains, totaling 21 outcomes.

Results: 60 of the 63 participants (32 randomized to yoga; 31 receiving standard of care) completed the study (one death in each arm and one withdrawal in yoga group). Analysis of covariance for week-12 scores, adjusting for baseline scores and confounders, revealed significant treatment effects favoring yoga in the L-IPF cough domain (-9.29 points, 95% CI -18.37 to -0.20; p=0.045), in the L-IPF total score (-7.11, 95% CI -13.15 to -1.06; p=0.022), and in the R-scale-PF cough domain (-1.18, 95% CI -2.27 to -0.10; p=0.034) in the study population.

Conclusion: Patients with idiopathic pulmonary fibrosis participating in a yoga program demonstrated significant improvement in quality of life assessed by the cough and total scores of L-IPF and the cough score of R-scale-PF than those receiving usual care.

Abstract word count: 247

Key words: Idiopathic Pulmonary Fibrosis, Yoga, Health-Related Quality-of-Life, Patient-Reported Outcome Measures, Cough.

TEXT

1. Introduction

Idiopathic pulmonary fibrosis carries significant mortality and symptom burden, with limited therapeutic options. Despite the discovery of antifibrotic agents that slow the rate of decline of forced vital capacity, patients living with idiopathic pulmonary fibrosis suffer from persistent respiratory symptoms and diminished quality of life. There are no available pharmacologic therapies for idiopathic pulmonary fibrosis that have been shown to impact patient-reported outcomes, such as symptoms or health-related quality-of-life. Though biomarkers such as forced vital capacity or image patterns may identify effects of interventions on biological pathways of the disease process, they likely do not fully encompass treatment impact on how patients 'feel, function, and survive,' and only weakly correlate with patient-reported symptom measures [2–4]. In this context, identification of treatment strategies for idiopathic pulmonary fibrosis with the aim of enhancing patients' quality of life is a top priority.

Yoga is a mind-body practice that has become an increasingly popular and effective method to treat and manage symptoms of chronic diseases, and is the most commonly used complementary health approach in the United States [5]. According to a 2017 national survey, about one in seven U.S. adults practiced yoga in the past 12 months, and the percentage of people practicing yoga grew from 2007 to 2017 [6]. A mounting body of literature demonstrates the benefits of yoga not only in components of general wellness including stress, mental/emotional health, and sleep quality, but has also been shown to improve symptoms

105 and quality of life in various chronic diseases including Chronic Obstructive Pulmonary
106 Disease, asthma, cancer, heart failure, arthritis, and chronic pain [7–12].

107 Although classical yoga includes other elements, yoga as commonly practiced in the United
108 States typically emphasizes standard components such as breathing exercises
109 (pranayama), postures (asanas), and meditation (dhyana). Central to asanas and
110 pranayama is diaphragmatic breathing, which may lead to improved chest expansion and
111 decreased work of breathing. Studies evaluating the benefits of yoga in chronic respiratory
112 diseases (largely asthma and Chronic Obstructive Pulmonary Disease) have shown
113 improvement in variables such as forced expiratory volume in 1 second, tidal volume and
114 minute ventilation, as well as increase in measures such as alveolar gas exchange and
115 improved submaximal and maximal oxygen consumption, in addition to quality of life [13–16].

116 We sought to assess the effect of a standardized virtual, modified yoga program (henceforth,
117 treatment) designed specifically for individuals with idiopathic pulmonary fibrosis at our
118 center, with the effect on health-related quality of life as a primary objective. We
119 hypothesized that a 12-week modified yoga program, designed specifically for individuals
120 with idiopathic pulmonary fibrosis, would improve health-related quality of life compared to
121 usual care, with effects potentially most pronounced for symptoms like cough and dyspnea
122 that might benefit from improved breathing techniques.

123

124

125 **2. Methods**

126 **2.1 Study design:** This study was a non-blinded, single center, randomized pilot trial
127 conducted by the Center for Interstitial Lung Diseases at the University of Washington
128 Medical Center. It was approved by the Institutional Review Board at the University of
129 Washington and registered with ClinicalTrials.gov (NCT02848625). The trial protocol,
130 including detailed statistical analysis plan appears in Sections 2 to 6 of Online Data
131 Supplement.

132

133 **2.2 Participants:** Consenting adults with idiopathic pulmonary fibrosis meeting criteria
134 established in 2018 by the American Thoracic Society, European Respiratory Society,
135 Japanese Respiratory Society, and Latin American Thoracic Society at time of screening were
136 eligible [17]. Exclusion criteria included comorbidities interfering with yoga (e.g.,
137 musculoskeletal discomfort), evaluation for lung transplant or hospice care, participation in
138 yoga and/or pulmonary rehabilitation outside of the study at screening and during the study
139 period. All patients were otherwise allowed to receive usual care for idiopathic pulmonary
140 fibrosis including treatment with *nintedanib* or *pirfenidone* and supplemental oxygen when
141 necessary, during the study period.

142

143 **2.3 Randomization and masking:** Eligible participants were randomly allocated in a 1:1
144 ratio to either the treatment arm (following the modified yoga program), or the control arm
145 (receiving standard of care and following usual activities) with stratification by supplemental
146 oxygen need prior to enrollment to account for disease severity. The randomization schedule

147 was prepared using computer-generated permuted random blocks of size 4 for each
148 stratum. The sequence of allocation was hidden from the investigators to prevent selection
149 bias. Participants, investigators, and providers were not blinded to intervention. See Figure
150 E1 of the Online Data Supplement for details on the study protocol.

151

152 **2.4 Procedures:** The modified yoga program consisted of seated postures, breathing, and
153 meditation exercises designed by 5 certified yoga instructors tailored for fibrosis patients
154 (see Table E1 and Section 9 of Online Data Supplement). Chair yoga, as used in our study, is
155 a gentler yoga alternative for older adults. Classical yoga with more strenuous movement
156 that may involve poses on the floor, significant joint and muscle stretching was considered
157 not to be appropriate for the typical idiopathic pulmonary fibrosis patient population. Chair
158 yoga is quite popular and many studios and training courses for its practice are available,
159 with prior studies demonstrating benefit in elderly patients [18].

160 The protocol was intended to be in-person, though was amended due to the COVID-19
161 pandemic to reduce exposure risk, with participants randomized to the treatment arm
162 participating in group sessions conducted virtually via Zoom in individuals' homes (5-6 per
163 group). Sessions lasted one hour, twice/week, for 12 consecutive weeks, led by a certified
164 yoga instructor. The same instructor led each group's sessions. Participants received a
165 secure link to a pre-recorded demo video to practice during their free time (see Section 4 of
166 Online Data Supplement).

167 Participants in the treatment group received a journal at the beginning of the program and
168 were encouraged to write in it at the end of each class (see Section 8 of Online Data
169 Supplement). Journal entries were used in the qualitative assessment of the program.
170 Attention control conditions were not implemented for the control group due to lack of
171 feasibility and resource limitations during the pandemic. All patients were evaluated in
172 person at baseline and after 12 weeks when lung function and 6-minute walk tests were
173 performed, and patient-reported outcome measurements were collected.

174

175 **2.5 Outcomes:** The *primary outcomes* measured were total/domain-specific scores from
176 seven validated health-related quality of life tools collected at baseline and at the end of the
177 12-week study period. These included the Living with Idiopathic Pulmonary Fibrosis
178 symptoms module (L-IPF symptoms), a recently developed and validated visual analog
179 scale (VAS) for IPF called Raghu scale for pulmonary fibrosis (R-Scale-PF), King's Brief
180 Interstitial Lung Disease questionnaire (K-BILD), EuroQol-Five-Dimensional Five-Level
181 questionnaire (EQ-5D-5L), Hospital Anxiety and Depression (HAD) Scale, Patient-Reported
182 Outcomes Measurement Information System Sleep Disturbance and Sleep-Related
183 Impairment (PROMIS SD and SRI), and Epworth Sleepiness Scale (ESS) [19–26].

184 *Secondary outcomes* included changes from baseline to 12 weeks in absolute and percent
185 predicted forced vital capacity (FVC), diffusing capacity of the lungs for carbon monoxide
186 (DLCO), and 6-minute walk distance (6MWD).

187

188 **2.6 Questionnaires for Patient Reported Outcomes**

189 *L-IPF questionnaire symptoms module:* The L-IPF symptoms module contains 15 items, with
190 the total score derived as the average of the dyspnea (7 items), cough (5 items), and
191 energy/fatigue (3 items) domains, each with a 24-hour recall period [19]. Each item is rated on
192 a 5-point scale (0-4), with higher scores connoting greater impairment. The minimum
193 clinically important difference estimates have been reported as 6 to 7 for the dyspnea
194 domain score and 4 to 5 points for the cough domain score, though these estimates were
195 investigated in a population of patients with progressive interstitial lung disease, other than
196 idiopathic pulmonary fibrosis, which does not specifically apply to our study population [27].

197 *R-scale-PF questionnaire:* The R-scale-PF is a visual analog scale assessing 5 domains
198 (cough, shortness of breath, fatigue, depressed mood, and overall sense of well-being). Each
199 domain score ranges from 0 to 10 with 0.5 increments. The total score ranges from 0 to 50
200 with lower numbers indicating better health-related quality of life [20]. A minimum clinically
201 important difference estimate has not yet been defined in fibrosis patients.

202 Details for the remaining utilized questionnaires including K-BILD, EQ-5D-5L, HADS, PROMIS
203 SD and SRI, and ESS are provided in Section 7 of Online Data Supplement.

204

205 **2.7 Statistical analysis**

206 *Study Design and Analysis Population:* This pilot trial utilized patient-reported outcomes as
207 primary outcomes, with sample size determined by feasibility rather than power

208 calculations, as well-defined data on clinically important differences were not available for
209 the fibrosis population in the implemented instruments. The primary analysis set was the
210 modified intention-to-treat population defined as all randomized participants with a week
211 12 visit

212 *Primary Analysis:* Between-group comparisons for outcome scores were conducted using
213 analysis of covariance (ANCOVA), adjusting for baseline questionnaire scores, age, sex, BMI,
214 and supplementary oxygen use. Any of the outcomes that demonstrated significant
215 improvement in the study population was considered a favorable outcome. All analyses
216 were conducted in R (version 4.4.1). Given this is a pilot trial, p-values were not adjusted for
217 multiple comparisons.

218 Missing data were handled via multiple imputation with chained equations. Sensitivity
219 analyses using complete cases were performed. For more information on missing data
220 handling as well as sensitivity analyses see Section 6 of Online Data Supplement.

221

222

223 **3. Results**

224 Between January 1-June 10, 2021, 63 consecutive, eligible patients provided consent. Thirty-
225 two were randomly assigned to yoga and 31 to the control group. Thirty (94%) of 32
226 participants in the yoga group and 30 (97%) of 31 participants in the control group completed
227 12 weeks of assessment (Figure 1) to form the study population. One participant from each

228 study arm was missing at least one week 12 questionnaires. DLCO data were not available
229 for one participant at baseline and four at week 12, one did not have week 12 FVC data, and
230 two participants were missing 6MWD at baseline and 4 at week 12.

231 Baseline demographics are presented in Table 1. Most participants were male (41 [68%] of
232 60), with mean age of 73.4 [SD 8.21] years. Median disease duration was 3.2 years. Most
233 characteristics are comparable between the treatment groups, with no clinically meaningful
234 differences. Participants had mild to moderate impairment in lung function at baseline
235 (mean FVC% predicted was 74.8 [SD 21.44] and % predicted DLCO was 54.0 [18.27]).
236 Twenty-two (37%) participants used supplemental oxygen. Fifty-one (85%) participants were
237 on background antifibrotic therapy with either *nintedanib* or *pirfenidone*. Comorbid
238 conditions included obstructive sleep apnea in 28 (47%) participants, emphysema in 5 (8%),
239 gastroesophageal reflux disease (confirmed by pH probe) in 25 (42%), and pulmonary
240 hypertension (confirmed by right heart catheterization) in 11 (18%).

241 In Table 2, adjusted comparisons between yoga and control groups for primary outcomes
242 using multiple imputation are reported. For the L-IPF cough domain, the yoga group showed
243 improvement from baseline score (mean 27.83 [SD = 25.69]) to week 12 (mean 18.10
244 [21.23]), while the control group remained stable (baseline: 24.83 [22.95]; week 12: 25.00
245 [22.09]). The imputation-based analysis showed a treatment effect that was borderline
246 statistically significant, favoring yoga (adjusted treatment effect: -9.29; 95% CI: [-18.37, -
247 0.20]; p=0.045). The yoga group showed improvement from baseline total L-IPF score (mean
248 30.84 [SD = 18.77]) to week 12 (mean 23.37 [16.49]), while the control group remained stable
249 (baseline: 26.49 [19.60]; week 12: 27.16 [19.92]). The imputation-based analysis showed a

250 treatment effect that was statistically significant, favoring yoga (adjusted treatment effect: -
251 7.11; 95% CI: [-13.15, -1.06]; p=0.022). In the R-scale-PF cough domain, the yoga group
252 demonstrated substantial reduction in cough (baseline: 3.20 [SD 2.64]; week 12: 2.07
253 [2.31]), whereas the control group showed a slight worsening (baseline: 2.87 [2.21]; week 12:
254 3.14 [2.56]). The imputation-based analyses demonstrated significant treatment effects (-
255 1.18; 95% CI: [-2.27, -0.10]; p=0.034). Figure E3 of Online Data Supplement graphically
256 depicts the distribution of cough domain scores via L-IPF, L-IPF total scores, and cough
257 domain scores via R-Scale-PF at baseline and week 12, shown separately for control and
258 treatment groups using violin plots with individual patient data points.

259 Figure 2 illustrates individual patient trajectories from baseline to week 12 for cough domain
260 scores measured by L-IPF and R-Scale-PF questionnaires as well as L-IPF total score by
261 study arm, with average changes indicated by solid black lines.

262 In Table E2 of Online Data Supplement, unadjusted and adjusted comparison between the
263 yoga and control groups for secondary outcomes are shown using the multiple imputation
264 approach. There were no significant differences in any of the secondary outcomes over 12
265 weeks.

266 Since the findings from the sensitivity analyses using complete cases were consistent with
267 those of the primary analyses, detailed results are presented in Table E3 of Online Data
268 Supplement. While not all p-values reflect statistical significance, the directionality of
269 treatment effects for all primary outcomes was consistent, with the yoga group generally

showing improvement and the control group showing either stability or slight worsening of scores.

There were no adverse effects related to yoga treatment. Attendance and participation in the yoga group was satisfactory, with 100% attendance by 21 of 30 participants at all 24 sessions. Apart from one participant missing 5 sessions due to an unanticipated personal matter, 8 other participants without full attendance did not miss more than 2 sessions throughout the program.

A qualitative content analysis was performed through participants' journals. Central themes identified leading to sense of improvement in overall well-being included social connection, managing fibrosis symptoms, changed mindset (Figure E2 of Online Data Supplement). Regarding social connection, participants reported feeling a sense of community and support during the program. Participants felt less self-conscious about experiencing symptoms (such as cough) and enjoyed speaking with others about their experiences and being able to monitor their progress alongside others who shared their diagnosis. Several participants reported incorporating more deliberate and controlled breathing techniques into daily activities, with improved knowledge and understanding of the connection between mind and body. From a mindset standpoint, participants reported feeling an increase in confidence in their ability and motivation to increase physical activity and push themselves despite their debilitating diagnosis.

4. Discussion

291 This pilot trial provides evidence that participants receiving 12-week modified yoga program
292 experienced improvements in health-related quality-of-life outcomes, particularly in the
293 cough domain scores of both the L-IPF and R-Scale-PF questionnaires, compared to those
294 who continued usual daily activities. The strength of this conclusion is bolstered by
295 consistency of results showing greater improvements in multiple quality of life
296 instruments—including HADS, K-BILD, total R-scale-PF score, PROMIS SRI and ESS,
297 following intervention in the yoga group than the control group.

298 To our knowledge, this is the first idiopathic pulmonary fibrosis clinical trial reporting
299 improvement in outcomes in the intervention group as primary endpoints. As emphasized
300 by a recent landmark international symposium involving patients, academic investigators,
301 and regulatory representatives, endpoints in idiopathic pulmonary fibrosis clinical trials
302 should resonate more closely with the tangible patient experience [2]. The integration of
303 adequately validated outcomes is an important step in this direction. The statistically
304 significant improvement in the L-IPF cough domain score (and numeric improvement in
305 KBILD score) in the yoga arm participants in our study is clinically meaningful to patients, as
306 both of these questionnaires were developed with input from idiopathic pulmonary fibrosis
307 patients and have undergone extensive validity and reliability testing [2,21,28]. In a patient
308 population with progressive interstitial lung disease, other than idiopathic pulmonary
309 fibrosis, Swigris et al. provided estimates of 4 to 5 points in the L-PF cough domain score as
310 a clinically meaningful threshold [27]. Although our study population included patients with
311 fibrosis only, the observed change in the L-IPF cough domain exceeded this threshold. The
312 inclusion of the recently developed R-Scale-PF as a health-related quality-of-life measure in

313 our study is aligned with evolving research in idiopathic pulmonary fibrosis aimed at
314 adopting psychometric tools such visual analogue scales that can be used to rapidly assess
315 the severity of symptoms and other traits in patients with idiopathic pulmonary fibrosis, in
316 both research and clinical settings [20,29–31]. Other scale tools, such as cough visual analogue
317 scale, carry prognostic and quality of life value in fibrosis and are being increasingly used in
318 interventional trials in idiopathic pulmonary fibrosis [32,33].

319 Previous studies have demonstrated a clear benefit of yoga in other chronic respiratory
320 diseases on validated health-related quality-of-life scores, including asthma and COPD
321 [8,9,34,35]. Our study is the first to evaluate the effect of yoga on patients with idiopathic
322 pulmonary fibrosis with positive findings despite the barrier of virtual rather than in-person
323 sessions due to the COVID-19 pandemic, particularly since previous data suggests
324 participant preference for in-person yoga classes [36]. Two unpublished results showed mixed
325 results regarding improvements in quality of life scores following participation in yoga,
326 although both were designed as feasibility/safety studies with less than 20 participants each
327 (one study in idiopathic pulmonary fibrosis patients and another in patients with fibrotic ILD
328 of any cause) [37,38]. We did not find statistically significant improvement in anxiety and
329 depression scores measured by the HADS in contrast to a previous study that evaluated a
330 general group of chronic lung disease patients awaiting lung transplant [39].

331 Although numerically greater improvements in the ESS and PROMIS SRI scores were
332 observed in the yoga group, our study did not show statistically significant benefit in sleep
333 quality despite prior reports showing improvement in sleep quality and insomnia with yoga
334 participation in other patient populations [40]. There is a complicated relationship with sleep

335 quality in idiopathic pulmonary fibrosis patients, in whom comorbid sleep related breathing
336 disorders such as OSA and insomnia are common and likely worsen the quality of life and
337 may even increase mortality in patients with idiopathic pulmonary fibrosis [41–43]. Another
338 factor reported to be potentially contributing to increased arousal index in idiopathic
339 pulmonary fibrosis is comorbid gastroesophageal reflux disease [41]. Further prospective
340 studies are needed to better evaluate the effects of yoga on overall sleep quality in idiopathic
341 pulmonary fibrosis patients.

342 Possibilities of the potential mechanism for improved quality of life in fibrosis patients
343 participating in yoga include improved posture, allowing more efficient use of abdominal and
344 diaphragmatic muscles. Implementation of pranayama practice optimizes breath control
345 and synchronization of movements with breath, which likely helps to manage symptoms of
346 breathlessness. Various yoga exercises such as deep diaphragmatic breathing can improve
347 vagal tone, which may help diminish enhanced cough reflex sensitivity as previously
348 described in patients with idiopathic pulmonary fibrosis [44].

349 The results of this study must be interpreted in the context of several limitations amidst its
350 strengths. First, this was a single center, pilot trial designed to assess feasibility with the aim
351 of informing future studies with adequate sample size calculations and powered to detect
352 significant differences in trial outcomes between groups. This was an exploratory pilot trial
353 designed primarily to assess feasibility and generate hypotheses for future studies. We
354 acknowledge that with multiple endpoints (21 in total) and no adjustment for multiple
355 comparisons, our findings are vulnerable to Type I error. However, the consistency of findings
356 across multiple cough-related measures strengthens our confidence in these specific

357 results. Future confirmatory trials should pre-specify primary endpoints and include
358 appropriate statistical adjustments. A second limitation is the relatively small sample size
359 and study duration of only 12 weeks. Third, since a blinded trial is not possible, it is difficult
360 to distinguish between yoga-specific and nonspecific benefits (e.g. expectation bias, social
361 connection during class, interpersonal skills of the yoga instructor). Finally, future trials
362 should include well-validated measures of cough such as The Leicester Cough
363 Questionnaire [45,46].

364 In summary, this is the first idiopathic pulmonary fibrosis clinical trial demonstrating
365 improvement in patient-reported outcomes as primary endpoints, and the first study to
366 evaluate the effect of yoga practice in this patient population. Besides demonstrating safety
367 and feasibility of a yoga program that patients can engage in from the comfort of their homes,
368 the study demonstrated improved health-related quality of life measures in patients with
369 idiopathic pulmonary fibrosis following participation in a yoga program supervised by
370 instructors. These results are clinically significant given the critical need for therapeutic
371 options that improve outcomes that are meaningful to patients suffering with this disease.
372 A larger, multi-center trial is warranted to further establish improved health-related quality
373 of life via participation in a yoga program tailored for patients with idiopathic pulmonary
374 fibrosis, in keeping with an emphasis on patient-centered outcomes.

REFERENCES

375 1. Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic Pulmonary Fibrosis (an Update) and
376 Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice
377 Guideline. *Am J Respir Crit Care Med*. 2022;205(9):e18-e47. doi:10.1164/rccm.202202-
378 0399ST

379 2. Raghu G, Ghazipura M, Fleming TR, et al. Meaningful Endpoints for Idiopathic
380 Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'.
381 Report of a Collaborative Discussion in a Symposium with Direct Engagement from
382 Representatives of Patients, Investigators, the National Institutes of Health, a Patient
383 Advocacy Organization, and a Regulatory Agency. *Am J Respir Crit Care Med*.
384 2024;209(6):647-669. doi:10.1164/rccm.202312-2213SO

385 3. Swigris JJ, Han M, Vij R, et al. The UCSD shortness of breath questionnaire has
386 longitudinal construct validity in idiopathic pulmonary fibrosis. *Respir Med*.
387 2012;106(10):1447-1455. doi:10.1016/j.rmed.2012.06.018

388 4. Aronson KI, Martin-Schwarze AM, Swigris JJ, et al. Validity and Reliability of the Fatigue
389 Severity Scale in a Real-World Interstitial Lung Disease Cohort. *Am J Respir Crit Care*
390 *Med*. 2023;208(2):188-195. doi:10.1164/rccm.202208-1504OC

391 5. *2016 Yoga in America Study Conducted by Yoga Journal & Yoga Alliance*.
392 https://www.yogaalliance.org/2016YogaInAmericaStudy

393 6. Clarke TC, Barnes PM, Black LI, Stussman BJ, Nahin RL. Use of Yoga, Meditation, and
394 Chiropractors Among U.S. Adults Aged 18 and Over. *NCHS Data Brief*. 2018;(325):1-8.

395 7. Selvan P, Hriso C, Mitchell J, Newberg A. Systematic review of yoga for symptom
396 management during conventional treatment of breast cancer patients. *Complement*
397 *Ther Clin Pract*. 2022;48:101581. doi:10.1016/j.ctcp.2022.101581

398 8. Holland AE, Hill CJ, Jones AY, McDonald CF. Breathing exercises for chronic obstructive
399 pulmonary disease. Cochrane Airways Group, ed. *Cochrane Database of Systematic*
400 *Reviews*. Published online October 17, 2012. doi:10.1002/14651858.CD008250.pub2

401 9. Yang ZY, Zhong HB, Mao C, et al. Yoga for asthma. *Cochrane Database Syst Rev*.
402 2016;4(4):CD010346. doi:10.1002/14651858.CD010346.pub2

403 10. Andrea Cortés-Ladino C, Augusto Arias-Ortiz W, Porras-Ramírez A. Effectiveness of
404 Yoga and Acupuncture in Rheumatoid Arthritis: A Systematic Review and Meta-
405 Analysis. *Evid Based Complement Alternat Med*. 2023;2023:9098442.
406 doi:10.1155/2023/9098442

407 11. Chow SL, Bozkurt B, Baker WL, et al. Complementary and Alternative Medicines in the
408 Management of Heart Failure: A Scientific Statement From the American Heart
409 Association. *Circulation*. 2023;147(2):e4-e30. doi:10.1161/CIR.0000000000001110

410 12. Qaseem A, Wilt TJ, McLean RM, et al. Noninvasive Treatments for Acute, Subacute, and
411 Chronic Low Back Pain: A Clinical Practice Guideline From the American College of
412 Physicians. *Ann Intern Med*. 2017;166(7):514-530. doi:10.7326/M16-2367

413 13. Vitacca M, Clini E, Bianchi L, Ambrosino N. Acute effects of deep diaphragmatic
414 breathing in COPD patients with chronic respiratory insufficiency. *Eur Respir J*.
415 1998;11(2):408-415. doi:10.1183/09031936.98.11020408

416 14. Goyeche JR, Ago Y, Ikemi Y. Asthma: The yoga perspective. Part I. The somatopsychic
417 imbalance in asthma: towards a holistic therapy. *J Asthma Res*. 1980;17(3):111-121.
418 doi:10.3109/02770908009105671

419 15. Satish V, Rao RM, Manjunath NK, et al. Yoga versus physical exercise for cardio-
420 respiratory fitness in adolescent school children: a randomized controlled trial. *Int J*
421 *Adolesc Med Health*. 2018;32(3). doi:10.1515/ijamh-2017-0154

422 16. Shaw I, Shaw BS, Brown GA. Role of diaphragmatic breathing and aerobic exercise in
423 improving pulmonary function and maximal oxygen consumption in asthmatics.
424 *Science & Sports*. 2010;25(3):139-145. doi:10.1016/j.scispo.2009.10.003

425 17. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An
426 Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med*.
427 2018;198(5):e44-e68. doi:10.1164/rccm.201807-1255ST

428 18. Park J, McCaffrey R, Newman D, Liehr P, Ouslander JG. A Pilot Randomized Controlled
429 Trial of the Effects of Chair Yoga on Pain and Physical Function Among Community-
430 Dwelling Older Adults With Lower Extremity Osteoarthritis. *J American Geriatrics*
431 *Society*. 2017;65(3):592-597. doi:10.1111/jgs.14717

432 19. Swigris JJ, Andrae DA, Churney T, et al. Development and Initial Validation Analyses of
433 the Living with Idiopathic Pulmonary Fibrosis Questionnaire. *Am J Respir Crit Care Med*.
434 2020;202(12):1689-1697. doi:10.1164/rccm.202002-0415OC

435 20. Scallan C, Strand L, Hayes J, et al. R-scale for pulmonary fibrosis: a simple, visual tool
436 for the assessment of health-related quality of life. *Eur Respir J*. 2022;59(1):2100917.
437 doi:10.1183/13993003.00917-2021

438 21. Patel AS, Siegert RJ, Brignall K, et al. The development and validation of the King's Brief
439 Interstitial Lung Disease (K-BILD) health status questionnaire. *Thorax*. 2012;67(9):804-
440 810. doi:10.1136/thoraxjnl-2012-201581

441 22. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr*
442 *Scand*. 1983;67(6):361-370. doi:10.1111/j.1600-0447.1983.tb09716.x

443 23. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness
444 scale. *Sleep*. 1991;14(6):540-545. doi:10.1093/sleep/14.6.540

445 24. EuroQol Group. EuroQol--a new facility for the measurement of health-related quality
446 of life. *Health Policy*. 1990;16(3):199-208. doi:10.1016/0168-8510(90)90421-9

447 25. Buysse DJ, Yu L, Moul DE, et al. Development and validation of patient-reported
448 outcome measures for sleep disturbance and sleep-related impairments. *Sleep*.
449 2010;33(6):781-792. doi:10.1093/sleep/33.6.781

450 26. Yu L, Buysse DJ, Germain A, et al. Development of short forms from the PROMIS™ sleep
451 disturbance and Sleep-Related Impairment item banks. *Behav Sleep Med*.
452 2011;10(1):6-24. doi:10.1080/15402002.2012.636266

453 27. Swigris JJ, Bushnell DM, Rohr K, Mueller H, Baldwin M, Inoue Y. Responsiveness and
454 meaningful change thresholds of the Living with Pulmonary Fibrosis (L-PF)
455 questionnaire Dyspnoea and Cough scores in patients with progressive fibrosing
456 interstitial lung diseases. *BMJ Open Respir Res*. 2022;9(1):e001167.
457 doi:10.1136/bmjresp-2021-001167

458 28. Swigris J, Cutts K, Male N, Baldwin M, Rohr KB, Bushnell DM. The Living with Pulmonary
459 Fibrosis questionnaire in progressive fibrosing interstitial lung disease. *ERJ Open Res*.
460 2021;7(2):00145-02020. doi:10.1183/23120541.00145-2020

461 29. Nolan CM, Birring SS. PROMising developments in IPF patient-reported outcome
462 measures. *Eur Respir J*. 2022;59(1):2102312. doi:10.1183/13993003.02312-2021

463 30. Moor CC, Mostard RLM, Grutters JC, Bresser P, Wijsenbeek MS. The use of online visual
464 analogue scales in idiopathic pulmonary fibrosis. *Eur Respir J*. 2022;59(1):2101531.
465 doi:10.1183/13993003.01531-2021

466 31. Swigris JJ, Pryor JB, Aronson KI, Guess TA, Solomon JJ. Interstitial Lung Disease Patients'
467 Global Impressions of Symptoms, Severity Ratings, and Meaningfulness of Changes
468 Over Time. *Ann Am Thorac Soc*. Published online August 12, 2024.
469 doi:10.1513/AnnalsATS.202405-457OC

470 32. Khor YH, Johannson KA, Marcoux V, et al. Epidemiology and Prognostic Significance of
471 Cough in Fibrotic Interstitial Lung Disease. *Am J Respir Crit Care Med*. Published online
472 March 27, 2024:rccm.202311-2101OC. doi:10.1164/rccm.202311-2101OC

473 33. Wu Z, Smith DJF, Yazbeck L, et al. Cough Severity Visual Analog Scale Assesses Cough
474 Burden and Predicts Survival in Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care*
475 *Med*. 2024;209(9):1165-1167. doi:10.1164/rccm.202311-2169LE

476 34. Anshu null, Singh N, Deka S, et al. The effect of yoga on pulmonary function in patients
477 with asthma: A meta-analysis. *Complement Ther Clin Pract*. 2023;50:101682.
478 doi:10.1016/j.ctcp.2022.101682

479 35. Cai Y, Ren X, Wang J, Ma B, Chen O. Effects of Breathing Exercises in Patients With
480 Chronic Obstructive Pulmonary Disease: A Network Meta-analysis. *Arch Phys Med*
481 *Rehabil*. 2024;105(3):558-570. doi:10.1016/j.apmr.2023.04.014

482 36. Brinsley J, Smout M, Davison K. Satisfaction with Online Versus In-Person Yoga During
483 COVID-19. *J Altern Complement Med*. 2021;27(10):893-896.
484 doi:10.1089/acm.2021.0062

485 37. Fell CD, Jessa I, Hatley S, Crawford L, Culos-Reed N. Yoga For Idiopathic Pulmonary
486 Fibrosis: A Pilot Study. In: *A42. NOVEL PHENOTYPES, OUTCOME MEASURES,*
487 *TREATMENT STRATEGIES, AND COMORBID ILLNESS*. American Thoracic Society;
488 2011:A1527-A1527. doi:10.1164/ajrccm-
489 conference.2011.183.1_MeetingAbstracts.A1527

490 38. Kreuter M, Wasmuth L, Kotzerke M, et al. Yoga in patients with fibrosing interstitial lung
491 diseases – a feasibility trial. In: *Idiopathic Interstitial Pneumonias*. European
492 Respiratory Society; 2020:773. doi:10.1183/13993003.congress-2020.773

493 39. Santana MJ, S-Parrilla J, Mirus J, Loadman M, Lien DC, Feeny D. An assessment of the
494 effects of Iyengar yoga practice on the health-related quality of life of patients with
495 chronic respiratory diseases: a pilot study. *Can Respir J*. 2013;20(2):e17-23.
496 doi:10.1155/2013/265406

497 40. Wang WL, Chen KH, Pan YC, Yang SN, Chan YY. The effect of yoga on sleep quality and
498 insomnia in women with sleep problems: a systematic review and meta-analysis. *BMC*
499 *Psychiatry*. 2020;20(1):195. doi:10.1186/s12888-020-02566-4

500 41. Hagmeyer L, Herkenrath SD, Treml M, Pietzke-Calcagnile A, Anduleit N, Randerath W.
501 Sleep-related breathing disorders in idiopathic pulmonary fibrosis are frequent and
502 may be associated with pulmonary vascular involvement. *Sleep Breath*.
503 2023;27(3):961-971. doi:10.1007/s11325-022-02686-z

504 42. Kolilekas L, Manali E, Vlami KA, et al. Sleep Oxygen Desaturation Predicts Survival in
505 Idiopathic Pulmonary Fibrosis. *Journal of Clinical Sleep Medicine*. 2013;09(06):593-
506 601. doi:10.5664/jcsm.2758

507 43. Troy LK, Young IH, Lau EMT, et al. Nocturnal hypoxaemia is associated with adverse
508 outcomes in interstitial lung disease. *Respirology*. 2019;24(10):996-1004.
509 doi:10.1111/resp.13549

510 44. van Manen MJG, Birring SS, Vancheri C, et al. Cough in idiopathic pulmonary fibrosis.
511 *Eur Respir Rev*. 2016;25(141):278-286. doi:10.1183/16000617.0090-2015

512 45. Birring SS. Development of a symptom specific health status measure for patients with
513 chronic cough: Leicester Cough Questionnaire (LCQ). *Thorax*. 2003;58(4):339-343.
514 doi:10.1136/thorax.58.4.339

515 46. Key AL, Holt K, Hamilton A, Smith JA, Earis JE. Objective cough frequency in Idiopathic
516 Pulmonary Fibrosis. *Cough*. 2010;6(1):4. doi:10.1186/1745-9974-6-4

517 47. Stanojevic S, Kaminsky DA, Miller MR, et al. ERS/ATS technical standard on interpretive
518 strategies for routine lung function tests. *Eur Respir J*. 2022;60(1):2101499.
519 doi:10.1183/13993003.01499-2021

FIGURE LEGENDS

1. **Figure 1:** CONSORT diagram.
2. **Figure 2:** Changes from baseline to week 12 for cough domain scores via L-IPF (panel A), total scores via L-IPF (panel B), and cough domain scores via R-Scale-PF (panel C), stratified by treatment arm. For all panels, each dot corresponds to a patient, either in the control group (left subpanels) or the treatment group receiving the modified yoga program (right subpanels). Patient observations from baseline to week 12 are joined by dashed lines, while the black solid line in each subpanel signifies the change in average domain score from baseline to week 12 in the control (left) or treatment (right) groups. Note that lower scores represent lesser symptoms/impairment.

530 **TABLES**

531 **Table 1. Baseline characteristics of the study population.**

	Control group (N=30)	Treatment group (N=30)	Overall (N=60)
Age (years)			
Mean (SD)	74.3 (7.41)	72.5 (8.97)	73.4 (8.21)
Body Mass Index (kg/m^2)			
Mean (SD)	26.5 (4.66)	27.6 (4.55)	27.1 (4.60)
Sex, n (%)			
Female	10 (33%)	9 (30%)	19 (32%)
Male	20 (67%)	21 (70%)	41 (68%)
Ethnicity, n (%)			
White	27 (90%)	27 (90%)	54 (90%)
Other	3 (10%)	3 (10%)	6 (10%)
Current/former smoker? n (%)			
No	19 (63%)	16 (53%)	35 (58%)
Yes	11 (37%)	14 (47%)	25 (42%)
Time since diagnosis (years)			
Median (Interquartile range)	3.6 (2.93)	3.0 (4.39)	3.2 (3.67)
[25th percentile – 75th percentile]	[2.31 – 5.24]	[1.92 – 6.30]	[2.21 – 5.88]
Surgical lung biopsy done? n (%)			
No	17 (57%)	19 (63%)	36 (60%)
Yes	13 (43%)	11 (37%)	24 (40%)
FVC (L)			
Mean (SD)	2.7 (0.77)	2.9 (0.86)	2.8 (0.82)
Median [25th percentile – 75th percentile]	2.7 [2.02 – 2.96]	3.1 [2.22 – 3.70]	2.8 [2.08 – 3.37]
FVC % predicted			
Mean (SD)	70.0 (21.84)	79.6 (20.28)	74.8 (21.44)
Median [25th percentile – 75th percentile]	70.5 [58.75 – 84.25]	77.5 [66.75 – 94.75]	73.0 [65.00 – 91.25]
DLCO (mmol/min/kPa)			
Mean (SD)	12.4 (3.41)	13.3 (4.42)	12.8 (3.93)
Missing	0 (0%)	1 (3.3%)	1 (1.7%)
DLCO % predicted value [*]			
Mean (SD)	52.5 (15.38)	56.0 (20.97)	54.0 (18.27)
Missing	0 (0%)	1 (3.3%)	1 (1.7%)
6MW distance (feet)			
Mean (SD)	1311 (405.7)	1269 (403.6)	1290 (401.7)
Missing	1 (3.3%)	1 (3.3%)	2 (3.3%)
Supplemental oxygen use, n (%) [†]			

	Control group (N=30)	Treatment group (N=30)	Overall (N=60)
Supplemental O2 not required	20 (67%)	18 (60%)	38 (63%)
Supplemental O2 required	10 (33%)	12 (40%)	22 (37%)
Obstructive sleep apnea reported, n (%)			
No	19 (63%)	13 (43%)	32 (53%)
Yes, without PAP therapy	4 (13%)	10 (33%)	14 (23%)
Yes, with PAP therapy	7 (23%)	7 (23%)	14 (23%)
Emphysema reported, n (%)			
No	29 (97%)	26 (87%)	55 (92%)
Yes	1 (3%)	4 (13%)	5 (8%)
Antifibrotics, n (%)			
No	3 (10%)	6 (20%)	9 (15%)
Yes	27 (90%)	24 (80%)	51 (85%)
Gastroesophageal reflux disease, n (%)			
No/Unknown	13 (43%)	15 (50%)	28 (47%)
Yes, confirmed by pH probe	14 (47%)	11 (37%)	25 (42%)
Yes, not confirmed by pH probe	3 (10%)	4 (13%)	7 (12%)
Pulmonary hypertension, n (%)			
No/Unknown	22 (73%)	16 (53%)	38 (63%)
Yes, confirmed by right heart catheterization	4 (13%)	7 (23%)	11 (18%)
Yes, not confirmed by right heart cath.	4 (13%)	7 (23%)	11 (18%)

Notes:
[*] Percent predicted FVC and DLCO calculated using GLI reference equations [47].
[†] Supplemental oxygen use is a stratification factor.

532

533 **Table 2. Changes from baseline to week 12 and adjusted treatment effect of modified yoga**

534 **program in primary outcomes for the study population.**

	*Baseline**	*Week 12**	*Change† (Week 12 – Baseline)*	*Adjusted Treatment Effect of Yoga‡*	
				Point estimate (95% CI)	*p-value*
Living with Idiopathic Pulmonary Fibrosis (L-IPF) (Cough)					
MYP	27.83 (25.69)	18.10 (21.23)	-9.31 (21.03)	-9.29 (-18.37, -0.20)	0.045
Control	24.83 (22.95)	25.00 (22.09)	0.17 (19.14)		
Living with Idiopathic Pulmonary Fibrosis (L-IPF) (Dyspnea)					
MYP	24.14 (21.81)	21.27 (20.02)	-1.61 (12.09)	-2.86 (-8.98, 3.27)	0.353
Control	21.27 (20.02)	22.86 (22.48)	0.99 (11.03)		
Living with Idiopathic Pulmonary Fibrosis (L-IPF) (Overall)					
MYP	30.84 (18.77)	23.37 (16.49)	-7.18 (13.57)	-7.11 (-13.15, -1.06)	0.022
Control	26.49 (19.60)	27.16 (19.92)	0.66 (10.70)		
Raghu Scale for Pulmonary Fibrosis (R-scale-PF) (Cough)					
MYP	3.20 (2s.64)	2.07 (2.31)	-0.97 (2.29)	-1.18 (-2.27, -0.10)	0.034
Control	2.87 (2.21)	3.14 (2.56)	0.28 (2.05)		
Raghu Scale for Pulmonary Fibrosis (R-scale-PF) (Shortness of Breath)					
MYP	4.13 (2.62)	4.00 (2.58)	0.00 (1.71)	-0.16 (-1.12, 0.80)	0.741
Control	3.27 (2.48)	3.66 (2.96)	0.38 (1.90)		
Raghu Scale for Pulmonary Fibrosis (R-scale-PF) (Fatigue)					
MYP	4.43 (2.45)	4.31 (2.88)	0.00 (2.20)	0.09 (-1.05, 1.24)	0.869
Control	3.67 (2.66)	3.83 (3.08)	0.14 (2.08)		
Raghu Scale for Pulmonary Fibrosis (R-scale-PF) (Mood)					
MYP	2.63 (2.61)	1.90 (2.54)	-0.79 (2.46)	-0.21 (-1.37, 0.96)	0.722
Control	1.63 (1.92)	1.48 (2.11)	-0.07 (2.09)		
Raghu Scale for Pulmonary Fibrosis (R-scale-PF) (Wellbeing)					
MYP	3.03 (1.88)	3.21 (2.35)	0.07 (2.46)	-0.57 (-1.81, 0.67)	0.362
Control	2.80 (2.04)	3.48 (2.95)	0.72 (2.17)		
Raghu Scale for Pulmonary Fibrosis (R-scale-PF) (Overall)					
MYP	17.43 (9.63)	15.48 (9.88)	-1.69 (8.65)	-2.27 (-6.68, 2.14)	0.306
Control	14.23 (8.84)	15.59 (10.93)	1.45 (7.60)		
King's Brief Interstitial Lung Disease (K-BILD) (Psychological)					
MYP	36.40 (10.52)	38.45 (9.10)	1.90 (8.51)	0.03 (-4.28, 4.35)	0.988
Control	40.20 (10.04)	40.17 (10.18)	-0.03 (9.95)		
King's Brief Interstitial Lung Disease (K-BILD) (Breathlessness and Activities)					
MYP	24.03 (8.72)	24.21 (7.89)	0.14 (4.76)	0.06 (-2.12, 2.25)	0.953
Control	25.57 (8.59)	25.63 (7.89)	0.07 (4.62)		
King's Brief Interstitial Lung Disease (K-BILD) (Chest Symptoms)					
MYP	11.27 (2.21)	11.93 (2.2)	0.62 (1.90)	0.24 (-0.61, 1.08)	0.578
Control	11.70 (2.31)	12.00 (2.12)	0.30 (1.58)		
King's Brief Interstitial Lung Disease (K-BILD) (Overall)					
Yoga	71.73 (17.79)	74.59 (17.27)	2.62 (11.73)	0.66 (-5.73, 7.04)	0.837
Control	77.57 (18.33)	77.80 (17.64)	0.23 (13.94)		
EuroQol-5D-5L (EQ-5D-5L) Visual Analogue Scale (VAS)					
MYP	70.53 (18.77)	70.76 (16.71)	0.90 (13.27)	2.60 (-3.56, 8.76)	0.400
Control	71.57 (21.88)	68.43 (21.66)	-3.13 (12.40)		
EuroQol-5D-5L (EQ-5D-5L) Index					

MYP	0.81 (0.11)	0.80 (0.16)	-0.01 (0.11)	0.00 (-0.05, 0.04)	0.853
Control	0.82 (0.10)	0.82 (0.12)	0.00 (0.07)		
Hospital Anxiety and Depression Scale (HADS) (Anxiety)					
MYP	4.80 (4.13)	3.90 (3.72)	-0.90 (2.87)	-0.10 (-1.28, 1.07)	0.859
Control	3.23 (2.49)	2.93 (2.66)	-0.17 (2.19)		
Hospital Anxiety and Depression Scale (HADS) (Depression)					
MYP	4.57 (3.82)	3.76 (3.52)	-0.90 (3.07)	-0.88 (-2.21, 0.46)	0.193
Control	4.17 (2.90)	4.28 (3.5)	0.17 (2.16)		
Hospital Anxiety and Depression Scale (HADS) (Overall)					
MYP	9.37 (7.45)	7.66 (6.68)	-1.79 (4.97)	-1.09 (-3.32, 1.14)	0.331
Control	7.40 (4.80)	7.17 (5.51)	-0.03 (3.59)		
Patient-Reported Outcomes Measurement Information System (PROMIS™) Sleep Disturbance (SD)					
MYP	45.29 (9.52)	45.80 (8.73)	0.89 (8.60)	2.45 (-1.03, 5.93)	0.163
Control	48.62 (9.48)	46.29 (9.6)	-2.13 (5.76)		
Patient-Reported Outcomes Measurement Information System (PROMIS™) Sleep-Related Impairment (SRI)					
MYP	47.32 (8.78)	45.77 (8.08)	-1.10 (7.62)	-1.82 (-5.63, 1.99)	0.342
Control	44.63 (9.61)	45.92 (10.66)	1.58 (7.66)		
Epworth Sleepiness Scale (ESS)					
MYP	7.03 (3.94)	6.03 (4.40)	-0.90 (2.92)	-0.70 (-2.44, 1.05)	0.427
Control	4.63 (2.92)	4.90 (3.57)	0.38 (3.16)		

Notes:

[*] Week 12 is the end of the intervention period. Mean (standard deviation) values were computed for all patients with complete data at baseline and week 12.

[†] We perform an unadjusted comparison of the change (week 12 – baseline) of each of the primary outcomes between the two study arms (treatment and control).

[‡] A linear regression model was used treatment differences at week 12 for outcomes, adjusting for age, sex, BMI, supplementary oxygen usage, and the baseline value of the specific outcome measure under consideration. To handle missing data, multiple imputation was performed using the chained equations method. Pooled estimates, confidence intervals (CIs), and p-values were obtained using Rubin's rules (N=60) with * denoting statistically significant findings at level 0.05.

535

536 **FIGURES**



537

538 **Figure 1:** CONSORT diagram.



Figure 2: Changes from baseline to week 12 for cough domain scores via L-IPF (panel A), total scores via L-IPF (panel B), and cough domain scores via R-Scale-PF (panel C), stratified by treatment arm.

1 **ONLINE DATA SUPPLEMENT**

2 **Title:** Yoga Effect on Quality-of-Life Study Among Patients with Idiopathic Pulmonary

3 Fibrosis (YES-IPF)

4 **Authors:** Suha Kadura, Soumik Purkayastha, Josh Benditt, Amit Anand, Bridget Collins,

5 Miguele De Quadros, Mafara Hobson, MJ Biswas, Lawrence Ho, Cathie Spino, Ganesh

6 Raghu*

7 ***Corresponding Author:** Ganesh Raghu, MD

8 University of Washington, Campus Box 356175, Seattle, WA 98195 USA

9 Email: graghu@uw.edu

1. Study title

Yoga effect on quality-of-life among patients with idiopathic pulmonary fibrosis (YES-IPF): A prospective, randomized control pilot trial by virtual means during the COVID-19 pandemic in Seattle, USA. ClinicalTrials.gov registration: NCT02848625 [link]

2. Background and Rationale

There has been ongoing debate regarding clinically meaningful endpoints for clinical trials involving patients with Idiopathic Pulmonary Fibrosis (IPF). Measurements of pulmonary function (forced vital capacity or FVC and diffusion capacity for Carbon Monoxide or DLCO) are often used, although it is often argued that assessing for change in quality of life measures and/or mortality would be more meaningful, patient centered outcomes [1].

There is only one study to date regarding the effect of yoga on the quality of life and physiologic measures of pulmonary function among patients with IPF. Fell et al presented an abstract in 2011 where patients with IPF participated in biweekly 75-minute yoga sessions for 4 weeks. At the end of 4 weeks, there were no significant changes in health-related quality of life (HRQoL) as measured by the SGRQ and SF-36 or in 6MWD. However, this study did demonstrate that a yoga program may be safe and feasible among patients with IPF. Yoga has been studied in other chronic lung diseases. Studies of the effect of yoga and associated breathing techniques on symptoms and physiologic parameters in patients with asthma have drawn variable conclusions [2,3]. Santana et al studied the effects of Iyenger yoga practice on patients with chronic lung disease awaiting lung transplant, 20% of whom had

IPF, and found that anxiety (by the Hospital Anxiety and Depression Score) and fatigue (Chronic Respiratory Questionnaire) scores were improved after 12 weeks [4]. A meta-analysis of 5 randomized controlled trials of COPD patients participating in yoga training demonstrated some improvement in FEV1 and 6MWD, although quality of life measures were not assessed [5]. This meta-analysis does, however, suggest that yoga programs can be completed safely among patients with chronic lung disease. While participation in pulmonary rehabilitation programs has been shown to improve dyspnea and quality of life in patients with IPF, and is in fact recommended in evidence based guidelines, the effect of complementary therapies requiring focused breathing techniques, such as yoga, on quality of life, dyspnea and pulmonary function in this patient population has not yet been studied [6–9].

Previous studies measuring quality of life in patients with IPF have used the St George's Respiratory Questionnaire (SGRQ), the short form 36 health survey (SF-36), EuroQol instrument, and A Tool to Assess Quality of life in IPF (ATAQ-IPF) [10]. In terms of differences within the population of IPF patients, the initial study for ATAQ-IPF found that scores were significantly different among patients who required supplemental O2 and those who did not, with greater impairment among the former [11].

We propose to perform a pilot study of the effect of yoga on quality of life among patients with IPF when compared to usual care. While Fell et al did not observe a significant change in quality of life, their program was only 4 weeks long, and there was not a control group. We will also measure any effect of yoga on pulmonary function measured by PFTs and 6MWD.

52

53 **3. Objectives**

54 *Primary:* Identify whether routine a modified yoga program/exercises 2 times per week x 12
55 weeks is associated with improved quality of life (measured by any of the 7 validated tools to
56 assess HRQOL) compared to usual care among patients with IPF. Questionnaires that will
57 be used include:

58 1. Living with Idiopathic Pulmonary Fibrosis questionnaire symptoms module (L-IPF
59 symptoms).
60 2. Raghu scale for pulmonary fibrosis, or R-Scale-PF.
61 3. Hospital Anxiety and Depression (HAD) Scale.
62 4. King's Brief Interstitial Lung Disease questionnaire (K-BILD).
63 5. EuroQol-Five-Dimensional Five-Level questionnaire (EQ-5D-5L).
64 6. Epworth Sleepiness Scale (ESS).
65 7. Patient-Reported Outcomes Measurement Information System Sleep Disturbance
66 and Sleep-Related Impairment (PROMIS SD and SRI).

67

68 *Secondary:* Determine whether IPF patients participating in MYP via Zoom classes x 12
69 weeks have

70 *1.* Improvement in FVC or less decline in FVC compared to control patients (usual care).
71 *2.* Improvement in 6-minute walk distance or less decline in 6-minute walk distance
72 compared to control patients (usual care)

4. **Trial Design:** Randomized controlled trial (nonblinded)

Study population: Patients with IPF with diagnosis in accordance with 2018 ATS/ERS/JRS/ALAT criteria for diagnosis and management of IPF seen at the Center for ILD, UWMC.

Outcomes

1. Primary outcome: Change in QOL as measured by any of the 7 HRQOL questionnaires.
2. Secondary outcomes: % change in FVC over 12 weeks, % change in 6-minute walk distance (vs actual change in distance) over 12 weeks.

Exposure: Yoga 2 times per week, 1 hour per session, for 12 weeks through the Modified Yoga Program. The Modified Yoga Program consists of:

1. Pranayama (breathing exercises)
2. Asanas (seated yoga postures)
3. Dhyana (guided meditation)
4. Taught by Certified Yoga Teacher (CYT)
5. 2 x/week for 12 weeks

Participants received a secure link to a pre-recorded demo video to practice during their free time.

Study population:

1. Include: Consecutive consented patients with IPF diagnosis seen in UWMC CILD
2. Exclude:
    a. Patients with active malignancy
    b. Comorbidities that would prohibitive: paralysis, musculoskeletal discomfort or broken limbs, etc.
    c. Patients being evaluate for lung transplant or receiving hospice care
    d. Patients regularly participating in yoga and/or pulmonary rehabilitation outside of the study at screening and during the study period

5. Methodology:

Sample size:

1. Acknowledging that this is the first study utilizing PROs as a primary outcome measure and was undertaken as a pilot trial, the study sample size was chosen based on feasibility considerations without formal power calculations.
2. Plan to randomize 60 eligible participants

3. Could consider power calculation based on KBILD MCID (MCID for KBILD in IPF is 3.9 points). Remaining PROs do not have clearly defined MCID for IPF.

Randomization method:

Eligible participants to be randomly allocated in a 1:1 ratio to yoga program or continuing "usual day-to-day activities," with stratification by need to have supplemental oxygen prior to study enrollment to account for disease severity.

1. Study statistician to prepare randomization schedule using computer-generated permuted random blocks of size 4 for each stratum.
2. Sequence of allocation hidden from investigators to prevent selection bias.

Potential confounding factors: Sex, Age, Prior or current experience with yoga, Weight, and Concomitant lung disease (mainly COPD or asthma)

Patient recruitment and consent:

1. Recruitment by nurse coordinators or study investigators.
2. Consent by study RNs

6. Statistical analysis plan:

Sample size/power calculation: The sample size for this pilot trial was determined based on feasibility, as MCIDs for HRQoL instruments in IPF are not well established. Given the exploratory nature of the study, hypothesis testing was conducted without p-value adjustment for multiple endpoints. Point estimates with 95% confidence intervals (CIs) were reported to compare treatment effects. The primary analysis set was the modified intention-to-treat population, defined as all randomized participants with a week 12 visit.

Exploratory analysis and modeling: Descriptive statistics were presented for baseline, week 12, and change-from-baseline values in primary and secondary outcomes. For continuous variables, means with standard deviations (SDs) or medians with interquartile ranges were reported; categorical variables were summarized as frequencies and percentages. Between-group comparisons for week 12 outcome scores were conducted using ANCOVA, adjusting for baseline outcome scores, age, sex, BMI, and supplementary oxygen use. All statistical analyses were performed in R, version 4.4.1.

Missing Data Handling: Missing data were addressed using multiple imputation with chained equations (MICE) using the mice package version 3.17.0 [12]. One hundred imputations were generated using Classification and Regression Trees (CART) as the imputation method. The imputation model included sex, BMI, age, and treatment arm as predictors, selected to ensure that all variables relevant to the analysis model were incorporated in the imputation

process. Each imputed dataset was analyzed separately using the pre-specified linear regression model with post-treatment score as the outcome, adjusted for baseline measurements, sex, BMI, age, oxygen levels, and treatment arm. Results from all 100 analyses were then pooled according to Rubin's rules to account for both within- and between-imputation variability [13]. This approach provides unbiased parameter estimates and correct standard errors under the missing at random (MAR) assumption. Stability of the results was supported by the large number of imputations utilized, which exceeds standard recommendations for complex analyses [14,15].

Sensitivity Analysis: Sensitivity analyses using complete cases were performed, applying the same ANCOVA model but including only participants with complete data for all variables. The robustness of the ANCOVA approach was assessed by checking the assumptions of normality of residuals (Shapiro-Wilk test), homogeneity of variance (Bartlett's test), and homogeneity of regression slopes (testing the interaction between baseline measurement and treatment arm). While 6 of the 21 outcomes examined demonstrated slight deviations from normality, our balanced design with adequate sample size (n=30 per group) ensures the robustness of ANCOVA to mild violations of normality [16]. The other ANCOVA assumptions were adequately met.

7. Description of questionnaires for PROs not included in main text:

170 *K-BILD questionnaire:* K-BILD contains 15 items, a seven-point Likert scale and three
171 domains (breathlessness and activities, psychological, and chest symptoms). The K-BILD
172 domain and total score ranges are 0–100; 100 represents best health status. The MCID for
173 the total K-BILD score is estimated to be 3.9 points in patients with ILD and IPF [17] .

174

175 *EQ-5D-5L:* The EQ-5D-5L assesses five dimensions including mobility, self-care, usual
176 activities, pain/discomfort and anxiety/depression. Each domain has five possible
177 responses that are combined to form a sum utility score which is then converted into a
178 specific index value using a country-specific set (in our case USA in English). Those
179 completing the questionnaire also rate their overall health on a 20 cm VAS with a score of 0
180 representing "the worse health you can imagine" and 100 representing "the best health you
181 can imagine"[18]. The MCID estimate for the EQ-5D-5L in patients with fibrotic ILD, including
182 IPF, ranges from 0.0050 to 0.054 and from 0.078 to 0.095 for the anchor-based and
183 distribution-based methods, respectively [19].

184

185 *HADS:* The HADS is a self-reporting rating scale of 14 items on a 4-point Likert scale (range
186 0-3). It is designed to measure anxiety and depression (7 items for each domain). The total
187 score is the sum of the 14 items, and for each domain the score is sum of the respective 7
188 items (ranging from 0-21). A higher score indicates higher distress [20]. There is not an
189 established MCID for the HADS questionnaire in IPF patients.

190

191 *PROMIS SD and SRI:* Sleep disturbance and sleep-related impairment are measured using

192 PROMIS 8-item short forms. Both measures use a 5-point Likert scale. Each raw score is

193 converted to a standardized T-score using conversion tables published on the PROMIS

194 website (nihpromis.org), with higher scores indicating greater sleep/wake disturbances [21].

195

196 *ESS:* The ESS score (the sum of 8 item scores, 0-3) ranges from 0-24. The higher the score,

197 the higher that person's average sleep propensity in daily life or their "daytime sleepiness"

198 [22].

199

200 **8. Journal format for treatment group study participants.**

Name: _____

My Yoga Journal

Date	Time & Length	Experiences in Meditation	Experiences in Activity	Additional Notes
	_____ AM/PM _____ min.			
	_____ AM/PM _____ min.			
	_____ AM/PM _____ min.			
	_____ AM/PM _____ min.			

"Yoga gives us a safe space and time to journey to the simplicity of breath and movement and connecting with ourselves." –Jill Conyers

9. Yoga session instructor script with pictures

INTRODUCTION : 5 minutes

Instructor: "Welcome to today's yoga session which should last about an hour. If you need to take a break at any time to use the restroom, cough or just catch your breath, please do so. The yoga practice we will do today is focused on relaxing and stretching and is not designed as vigorous exercise. Our practice will be to incorporate awareness of our breath with very gentle poses to expand our chest and relieve tightness in our muscles.

The session today is divided into 4 parts: 1. A few minutes of settling in, 2. A 25-minute session of gentle stretching postures, 3. A roughly 15-minute period of breathing exercises and 4. A 5-minute guided meditation to end the session.

Feel free to ask questions at any time, to stop the postures or exercises to take a break or just to sit quietly. This is your session.

First off, how are you doing today? Do you feel well enough to participate in the session today? If not, do not worry. You are welcome to stay with the group and just listen and do any of the practice that you feel able to. If you prefer to sign off the call, that is fine too. Again, these sessions are for you."

SETTLING IN: 5 minutes

Instructor: "Take time to get seated comfortably. It's better is you use a chair with a straight back. If you can, sit forward in the chair in the upright position away from the backrest. If not, it is okay to use the back for support.

It is now time to get in touch with your breath. You are welcome to close your eyes and take off your shoes. Maybe try planting your feet hip width apart and align your ankles directly underneath your knees. Extend your neck with a slight tuck of the chin and lengthen your spine fully. Allow your arms to relax, and rest your palms face up or face down on your thighs. Bring your shoulders back in line with the hips. Keep your chin level and draw it in slightly so the head moves back in line with the shoulders.

We are trying to create a conscious stability from the base of your spine to the crown of your head where you can feel at ease to breathe. Good posture promotes increased breath awareness because there is suddenly much more room to take big, deep breaths.

Keeping your eyes closed, begin to bring your attention to your breath. Just notice where your breath is right now in your body? Be curious about how you are breathing. How long is your inhale? Your exhale? Notice what part of your body you are using most to breathe: your belly, your chest, the back or front of your body, or is it just up top in the neck and shoulders? Let the sounds of the environment fade into the background and let the sound of your breath and the experience of the air moving in and out your lungs come to the foreground. Focus on an open, expansive inhale, filling your lungs from the bottom to the top and a smooth, slow exhale engaging your belly to press the air out of the lungs.

PAUSE to allow time for students to breathe

Allow all the thoughts of your day to fade, bring your attention if it wanders to the breath and the body. Lengthen your inhale and slow down the exhale, breathing out through your mouth. Maintain awareness of your posture, and continue to release excess tension with each exhale, breathe the tension out. If the mind wanders, gently invite your attention back, and follow the experience of the breath moving in and out of the body.

PAUSE again.

And now, gently open your eyes, and prepare for some gentle stretching. If you have any discomfort during these movements, please feel free to ask your instructor to assist you in modifying any of the exercises. If you feel the urge to cough during any of the exercises, feel free to take a rest and do so.

SEATED EXERCISES: 25 minutes

1. SEATED "MOUNTAIN" POSE:

Instructor: We will start with the seated mountain pose. Sit with your spine and neck straight and positioned with the shoulders over the hips. Place your hands, palm faced down on your thighs. Take four or five deep breaths in this position.

PAUSE to allow the students to practice.

"Mountain" pose is very restful and is a good point to start each of the other poses from. You can use it as an intermediate stop before you go on to your next pose. It is a very "centering" position for you.

2. SHOULDER CIRCLES:

   With your hands at your sides, gently move your shoulders in a circle. Start by making a forward circular motion for 5 repetitions. (INSTRUCTOR DEMONSTRATE)

   Then roll the shoulders in the opposite direction for 5 repetitions. (INSTRUCTOR DEMONSTRATE).

   Move into your mountain pose for one or two breaths and relax.

3. SUPPORTED NECK STRETCH:

Instructor: Next, we will very gently stretch the neck. Place your right hand on the crown of your head with the fingers over the temple. If your shoulder does not feel comfortable in that position, you may leave the arm at your side and stretch the neck gently using the weight of your head. Straighten your left arm down slightly away from your side, keeping the elbow and the wrist extended while stretching out the fingers fully. Gently pull your head to the right and hold for 10 seconds.

PAUSE

Drop your hands to your sides. Repeat the same stretch but this time on the opposite side with your left hand on the crown of your head and your right arm extended to the side. Gently pull your head to the left, while straightening out your right arm slightly away from your side. Keep the elbow and the wrist extended for 10 seconds. Return to mountain pose for two or three relaxing breaths.

4. SEATED “CAT/COW” POSE:

In “cow/cat” pose, move your hands, palms face-down to your knees. Inhale, gently lifting your gaze upward and allowing your spine to arch forward imitating the spine of a cow. Exhale, slowly dropping your chin to your chest, allow your spine to gently round backwards like a cat. This should be a gentle motion, not forced or uncomfortable. It is helpful to synchronize the breath with the movement of the spine. Breath in, gentle arching of the spine while looking up, breath out, gently rounding the spine. Performing 5 to 7 repetitions of arching and rounding, coupled with the breath is ideal.

PAUSE to allow the students to finish.

Bring yourself back to mountain pose and relax.

5. SEATED SIDE BENDS:

Instructor: Next we will do seated side bends. Starting from mountain pose, raise your left arm slowly (with your palm facing the ceiling) above your head straight up. Very gently, begin bending laterally to the right. Do not force this. There should be no pinching or discomfort in the spine or ribs. Breathe in and out for 4 or 5 breaths in this position. PAUSE.

You may notice that as you exhale you are able to bend slightly deeper. Gently return to the upright position and bring your left arm down. Now, raise your RIGHT arm up and bend gently to the left side. Again, do not force this bend. Take 4 or 5 breaths in this position.

PAUSE.

Gently return to the upright position and drop your right arm down.

6. SEATED SPINAL TWIST

Instructor: " Our next posture is the seated spinal twist. Starting again from the relaxed mountain pose with your spine straight and long, gently and slowly twist to the left placing your left forearm on the back of your chair. Place your right hand on your left thigh or the left edge of the seat and relax. To deepen the stretch, exhale and GENTLY pull with your right hand. Do not force this. There should be no pain in the spine. If there is any discomfort, back out of this position and tell your instructor. If you are comfortable take 4 or 5 breaths in this position and then return to mountain pose. Begin the twist on the right side by gently twisting to the right and placing your right forearm on the back of your chair. Place your left hand on your right thigh or the edge of the chair and, if you are comfortable, gently deepen the twist by pulling with your left hand. Take 4 or 5 breaths in this position. Return to mountain pose when you are finished. "

Breathing Exercises: 15 minutes

Instructor: How do you feel after our gentle yoga poses? If you need to take a drink, relax or change positions, go ahead. In our next exercises, we will be focused on our breath.

1. Counted breaths:

Instructor: In this exercise, we will use a metronome that I will set up for us and set a relaxed pace to help you begin to focus on the length of your inhales and exhales. Sitting in a relaxed position with your spine straight (seated mountain pose works great) we will use the

metronome to count 3 counts during inhalation and 3 counts during exhalation. Later as we become more experienced, we gradually make the exhalation longer than inhalation but now we will focus on making inhalation and exhalation equal. It is best if you can breathe in and out through your nostrils but if you cannot, through the mouth is fine or in through the nose and out through the mouth.

Instructor: continue this for about one minute and then give the group a break. Any questions?

2. Counted "victory breaths" (ujjayi)

Instructor: In this breathing exercise we will be performing the same exercise as we just did but we will be adding something called ujjayi or victory breathing. Victory breathing is performed by very slightly constricting the throat to make a soft sound like waves on the beach. A way to think of the sound is if you are trying to clean a pair of sunglasses by fogging them up before you clean them. DEMONSTRATE TO PARTICIPANTS (i.e. Darth Vader breath or AAAH and HAAA). Take a breath in and exhale like you are trying to fog the glasses and listen to the sound (this is the sound of the victory breath).Then with the same slight constriction of the throat, take a breath in. Again, if possible, you should breath in and out through your nose. Practice taking several breaths in this way and we will then use the metronome and once again count three beats to inhale and three beats to exhale.

Instructor: Have them do this for 45-60 seconds or about 10 breaths. How did that feel? Any questions?

3. Cooling Breath:

Instructor: For this breath technique, which involves drawing air across your tongue and into your mouth, having a “cooling or calming” effect on the nervous system, can be done one of two ways. You can curl the sides of your tongue inward, like you are sucking air through a straw, or if you can’t do that, you can sit your tongue right behind your front teeth and draw air in around your tongue. DEMONSTRATE.

Instructor: Have them practice and once questions are answered have them perform the cooling breath for about 30 seconds.

Brahmari (Buzzing Bee) Breath:

Place your thumbs in your ears and your tips of the fingers over your closed eyelids. Take a deep breath in. Then, while **exhaling, generate a LOUD humming noise so as to feel this vibration resonate through the face and the scalp**. DEMONSTRATE. Make sure you exhale fully allowing the subsequent inhale to be even deeper. Do this for 5 to 7 breaths at your own pace, with the tone that seems most comfortable. Then release the hands onto the thighs and let the breathing settle. Feel the warmth and the calm envelop you.

CLOSING GUIDED MEDITATION: 5 minutes

Instructor: Come into a position that is comfortable for you. Let the legs feel heavy. Soften your jaw. Bring your attention once again to your breath. You can breathe slowly keeping inhalation and exhalation slow and in a pattern and rate that feels relaxed and comfortable. Let your whole body melt into the chair, letting go of stiffness or tension in the spine. If your mind becomes distracted by thought, return your awareness to your breath, this inhalation, and this exhalation, being mindful to keep your attention focused in the present moment without trying to change it, and letting everything else be as it is.

Continue to allow your body to relax. Breathe in, breathe out. Take a big cleansing breath and breathe the tension out of your body. You can even make an audible ahhh sound on your next exhale. Let's try this together, inhale deeply and on your next exhale, open the mouth…ahhhh. One more. Feel the relaxation beginning at the bottom of your feet. Relax your toes.

Let the relaxation spread over your feet and up your ankles, spreading up your calves, and into your knees, softening the backs of your knees and releasing any tension or stiffness in your knees. Feel the relaxation spreading up your legs, feel the tension melt away in your hips and lower back. Release any tension in your lower back. Allow the relaxation to spread upward to your upper back and shoulders. Let go of tension in the shoulders. Feel the relaxation spread up the front of your body starting with your belly, let it be soft, rising and falling with each breath. Let your chest relax, slide your shoulder back, giving you a little more room to breathe easy. Now feel your upper arms relax and let the feeling spread into your elbows and forearms. Let go of tension or stiffness in the hands, relax the palm of your hand, the back of your hand, relax your fingers. Your hands, your arms, feel heavy and warm.

Feel your body unwind even further as you expand your chest open on each inhale and you feel your collar bones widen and relax down. Allow your shoulder blades to ease back slightly and continue to breathe deeply. Deep inhale, slow exhale. Notice your shoulders and your neck, let go of the tension in your neck. Feel the relaxation continue to your chin, let your jaw slacken, release your tongue from the roof of your mouth. Let your eyelids be heavy and relaxed, letting your eyeballs drift back. Notice your eyebrows unfurrowing and relaxing down, let your forehead become smooth and cool; the back of your head relaxes. Let the feeling of relaxation spread to the crown of your head; from the tips of your toes to the top of your head, your entire body is now calm and relaxed. Continue to feel the relaxation and sense of calm flow throughout your body from your head to your feet and back. Notice all of the muscles in your body relaxing completely. Feel your spine lengthen and melt into the chair, your limbs are heavy and warm. Continue to breathe smoothly and slowly as you mentally scan your body, looking for any remaining tension. If you notice any tension, focus on that area and direct the relaxation to flow into that area, carrying away any residual tension.

Relax and return to your Mountain pose. Do you have an questions or thoughts you would like to bring up ? How does everyone feel now that we have completed our session for today ?

REFERENCES

1. Raghu G, Collard HR, Anstrom KJ, et al. Idiopathic Pulmonary Fibrosis: Clinically Meaningful Primary Endpoints in Phase 3 Clinical Trials. *Am J Respir Crit Care Med*. 2012;185(10):1044-1048. doi:10.1164/rccm.201201-0006PP

2. Cramer H, Posadzki P, Dobos G, Langhorst J. Yoga for asthma: a systematic review and meta-analysis. *Ann Allergy Asthma Immunol*. 2014;112(6):503-510.e5. doi:10.1016/j.anai.2014.03.014

3. Cooper S, Oborne J, Newton S, et al. Effect of two breathing exercises (Buteyko and pranayama) in asthma: a randomised controlled trial. *Thorax*. 2003;58(8):674-679. doi:10.1136/thorax.58.8.674

4. Santana MJ, S-Parrilla J, Mirus J, Loadman M, Lien DC, Feeny D. An assessment of the effects of Iyengar yoga practice on the health-related quality of life of patients with chronic respiratory diseases: a pilot study. *Can Respir J*. 2013;20(2):e17-23. doi:10.1155/2013/265406

5. Liu XC, Pan L, Hu Q, Dong WP, Yan JH, Dong L. Effects of yoga training in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. *J Thorac Dis*. 2014;6(6):795-802. doi:10.3978/j.issn.2072-1439.2014.06.05

6. Nishiyama O, Kondoh Y, Kimura T, et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. *Respirology*. 2008;13(3):394-399. doi:10.1111/j.1440-1843.2007.01205.x

7. Vainshelboim B, Oliveira J, Yehoshua L, et al. Exercise training-based pulmonary rehabilitation program is clinically beneficial for idiopathic pulmonary fibrosis. *Respiration*. 2014;88(5):378-388. doi:10.1159/000367899

8. Huppmann P, Sczepanski B, Boensch M, et al. Effects of inpatient pulmonary rehabilitation in patients with interstitial lung disease. *Eur Respir J*. 2013;42(2):444-453. doi:10.1183/09031936.00081512

9. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *Am J Respir Crit Care Med*. 2011;183(6):788-824. doi:10.1164/rccm.2009-040GL

10. Idiopathic Pulmonary Fibrosis Clinical Research Network, Zisman DA, Schwarz M, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. *N Engl J Med*. 2010;363(7):620-628. doi:10.1056/NEJMoa1002110

11. Swigris JJ, Wilson SR, Green KE, Sprunger DB, Brown KK, Wamboldt FS. Development of the ATAQ-IPF: a tool to assess quality of life in IPF. *Health Qual Life Outcomes*. 2010;8:77. doi:10.1186/1477-7525-8-77

12. Buuren S van, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. *Journal of Statistical Software*. 2011;45:1-67. doi:10.18637/jss.v045.i03

13. Raghunathan T. *Missing Data Analysis in Practice*. 0 ed. Chapman and Hall/CRC; 2015. doi:10.1201/b19428

14. Graham JW, Olchowski AE, Gilreath TD. How many imputations are really needed? Some practical clarifications of multiple imputation theory. *Prev Sci*. 2007;8(3):206-213. doi:10.1007/s11121-007-0070-9

15. Bodner TE. What Improves with Increased Missing Data Imputations? *Structural Equation Modeling: A Multidisciplinary Journal*. 2008;15(4):651-675. doi:10.1080/10705510802339072

16. Glass GV, Peckham PD, Sanders JR. Consequences of Failure to Meet Assumptions Underlying the Fixed Effects Analyses of Variance and Covariance. *Review of Educational Research*. 1972;42(3):237-288. doi:10.2307/1169991

17. Nolan CM, Birring SS, Maddocks M, et al. King's Brief Interstitial Lung Disease questionnaire: responsiveness and minimum clinically important difference. *Eur Respir J*. 2019;54(3):1900281. doi:10.1183/13993003.00281-2019

18. EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. *Health Policy*. 1990;16(3):199-208. doi:10.1016/0168-8510(90)90421-9

19. Tsai APY, Hur SA, Wong A, et al. Minimum important difference of the EQ-5D-5L and EQ-VAS in fibrotic interstitial lung disease. *Thorax*. 2021;76(1):37-43. doi:10.1136/thoraxjnl-2020-214944

20. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand*. 1983;67(6):361-370. doi:10.1111/j.1600-0447.1983.tb09716.x

21. Yu L, Buysse DJ, Germain A, et al. Development of short forms from the PROMIS™ sleep disturbance and Sleep-Related Impairment item banks. *Behav Sleep Med*. 2011;10(1):6-24. doi:10.1080/15402002.2012.636266

22. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. *Sleep*. 1991;14(6):540-545. doi:10.1093/sleep/14.6.540

FIGURE LEGENDS

1. **Figure E1:** Study Protocol.
2. **Figure E2:** Central themes contributing to improved sense of well-being among yoga participants.
3. **Figure E3:** Cough domain score via the Living with Idiopathic Pulmonary Fibrosis scale (L-IPF) (panel A), total score via the Living with Idiopathic Pulmonary Fibrosis scale (L-IPF) (panel B), and cough domain score via the Raghu scale for pulmonary fibrosis (R-Scale-PF) (panel C) from baseline to week 12. Each dot corresponds to a patient, either in the control group (left panel) or the treatment group following the modified yoga program (right panel). Patient observations are overlaid on top of violin plots and displayed twice within each panel: once at baseline and again at week 12. Lower scores represent lesser symptoms/impairment.

TABLES

Table E1: Description of yoga poses.

Pose name	Description	Frequency	Duration
Asanas (postures)			
Parvatasana (seated mountain pose)	Straight back, lengthen up spine, relax shoulders down, neutral chest/diaphragm, deep breaths	Starting point prior to subsequent poses	2 min
Chair seated shoulder circles	Roll shoulders in a circular motion (both directions, 5 repetitions)	1 round	2 min
Seated neck stretches	Gently pull head to each side and hold	1 round	2 min
Marjayasana-bitilasana (seated cat cow pose)	Inhale and arch spine forward, exhale and round spine backwards	5-7 repetitions	4 min
Parsva Sukhasana (seated side bend pose)	Raise arm and bend laterally to each side	1 round	2 min
Ardha Matsyendrasana (seated spinal twist)	Twist to each side, rotating the spine, opening shoulders and chest	1 round	3 min
Pranayama (breathing exercises)			
Counted breaths	Through nostrils, 3 counts inhalation, 3 counts exhalation using metronome to set pace	1 round	1 min
Ujjayi (counted “victory breaths”	As above, adding throat constriction	1 round	1 min
Cooling breath	Curl sides of tongue inward, inhale, exhale	1 round	30 sec
Brahmari (buzzing bee breath)	Place thumbs in ears and fingers over closed eyelids, inhale, exhale with loud humming noise	1 round	1 min
Dhyana (meditation)			
Guided mediation	N/A	1 round	5 min

Table E2: Changes from baseline to week 12 and adjusted treatment effect of modified yoga program on secondary endpoints for the study population.

	Baseline [*]	*Week 12* [*]	*Change* [†] *(Week 12 – Baseline)*	*Adjusted Treatment Effect of Yoga* [‡]	
				Point estimate (95% CI)	*p-value*
Absolute Forced Vital Capacity (FVC) (L)					
MYP	2.95 (0.86)	2.82 (0.86)	-0.11 (0.23)	0.02 (-0.19, 0.23)	0.88
Control	2.67 (0.77)	2.54 (1.02)	-0.13 (0.54)		
Percent Predicted Forced Vital Capacity (FVC) (%)					
MYP	79.57 (20.28)	77.07 (21.97)	-2.55 (6.09)	0.25 (-6.99, 7.49)	0.94
Control	70.03 (21.84)	70.63 (24.80)	0.60 (19.06)		
Absolute Diffusing capacity or transfer factor of the lung for carbon monoxide (DLCO) (ml/min/kPa)					
MYP	13.27 (4.42)	12.08 (3.93)	-1.18 (1.88)	-0.41 (-1.66, 0.84)	0.51
Control	12.38 (3.41)	11.50 (4.60)	-0.85 (2.66)		
Percent Predicted Diffusing capacity or transfer factor of the lung for carbon monoxide (DLCO) (%)					
MYP	56.03 (20.97)	52.48 (20.28)	-3.11 (12.03)	-0.73 (-7.10, 5.63)	0.82
Control	52.47 (15.38)	49.79 (19.98)	-2.28 (11.25)		
6-minute walking test (6MWT) (feet)					
MYP	1268.79 (403.62)	1195.37 (383.21)	-69.92 (143.71)	83.49 (-30.09, 197.08)	0.15
Control	1311.07 (405.74)	1166.76 (526.65)	-146.07 (279.52)		

Notes:
[*] Week 12 is the end of the intervention period. Mean (standard deviation) values were computed for all patients with complete data at baseline and week 12.
[†] We perform an unadjusted comparison of the change (week 12 – baseline) of each of the primary outcomes between the two study arms (treatment and control).
[‡] A linear regression model was used treatment differences at week 12 for outcomes, adjusting for age, sex, BMI, supplementary oxygen usage, and the baseline value of the specific outcome measure under consideration. To handle missing data, multiple imputation was performed using the chained equations method. Pooled estimates, confidence intervals (CIs), and p-values were obtained using Rubin's rules (N=60).

512 **Table E3: Complete case analysis for changes from baseline to week 12 and adjusted**

513 **treatment effect of modified yoga program on primary endpoints for the study**

514 **population.**

	*Baseline**	*Week 12**	*Change† (Week 12 – Baseline)*	*Adjusted Treatment Effect of Yoga‡*	
				Point estimate (95% CI)	*p-value*
Living with Idiopathic Pulmonary Fibrosis (L-IPF) (Cough)					
MYP	27.83 (25.69)	18.10 (21.23)	-9.31 (21.03)	-8.59 (-17.50, 0.33)	0.065
Control	24.83 (22.95)	25.00 (22.09)	0.17 (19.14)		
Living with Idiopathic Pulmonary Fibrosis (L-IPF) (Dyspnea)					
MYP	24.14 (21.81)	21.27 (20.02)	-1.61 (12.09)	-2.93 (-8.77, 2.90)	0.329
Control	21.27 (20.02)	22.86 (22.48)	0.99 (11.03)		
Living with Idiopathic Pulmonary Fibrosis (L-IPF) (Overall)					
MYP	30.84 (18.77)	23.37 (16.49)	-7.18 (13.57)	-7.14 (-13.06, -1.23)	0.022
Control	26.49 (19.60)	27.16 (19.92)	0.66 (10.70)		
Raghu Scale for Pulmonary Fibrosis (R-scale-PF) (Cough)					
MYP	3.20 (2s.64)	2.07 (2.31)	-0.97 (2.29)	-1.19 (-2.24, -0.14)	0.031
Control	2.87 (2.21)	3.14 (2.56)	0.28 (2.05)		
Raghu Scale for Pulmonary Fibrosis (R-scale-PF) (Shortness of Breath)					
MYP	4.13 (2.62)	4.00 (2.58)	0.00 (1.71)	-0.08 (-1.01, 0.84)	0.859
Control	3.27 (2.48)	3.66 (2.96)	0.38 (1.90)		
Raghu Scale for Pulmonary Fibrosis (R-scale-PF) (Fatigue)					
MYP	4.43 (2.45)	4.31 (2.88)	0.00 (2.20)	0.09 (-1.05, 1.22)	0.884
Control	3.67 (2.66)	3.83 (3.08)	0.14 (2.08)		
Raghu Scale for Pulmonary Fibrosis (R-scale-PF) (Mood)					
MYP	2.63 (2.61)	1.90 (2.54)	-0.79 (2.46)	-0.18 (-1.30, 0.95)	0.757
Control	1.63 (1.92)	1.48 (2.11)	-0.07 (2.09)		
Raghu Scale for Pulmonary Fibrosis (R-scale-PF) (Wellbeing)					
MYP	3.03 (1.88)	3.21 (2.35)	0.07 (2.46)	-0.54 (-1.79, 0.70)	0.395
Control	2.80 (2.04)	3.48 (2.95)	0.72 (2.17)		
Raghu Scale for Pulmonary Fibrosis (R-scale-PF) (Overall)					
MYP	17.43 (9.63)	15.48 (9.88)	-1.69 (8.65)	-2.12	0.336

Control	14.23 (8.84)	15.59 (10.93)	1.45 (7.60)	(-6.39, 2.16)	
King's Brief Interstitial Lung Disease (K-BILD) (Psychological)					
MYP	36.40 (10.52)	38.45 (9.10)	1.90 (8.51)	0.33 (-3.85, 4.50)	0.879
Control	40.20 (10.04)	40.17 (10.18)	-0.03 (9.95)		
King's Brief Interstitial Lung Disease (K-BILD) (Breathlessness and Activities)					
MYP	24.03 (8.72)	24.21 (7.89)	0.14 (4.76)	0.05 (-2.09, 2.20)	0.960
Control	25.57 (8.59)	25.63 (7.89)	0.07 (4.62)		
King's Brief Interstitial Lung Disease (K-BILD) (Chest Symptoms)					
MYP	11.27 (2.21)	11.93 (2.2)	0.62 (1.90)	0.27 (-0.54, 1.08)	0.514
Control	11.70 (2.31)	12.00 (2.12)	0.30 (1.58)		
King's Brief Interstitial Lung Disease (K-BILD) (Overall)					
Yoga	71.73 (17.79)	74.59 (17.27)	2.62 (11.73)	1.09 (-5.11, 7.28)	0.733
Control	77.57 (18.33)	77.80 (17.64)	0.23 (13.94)		
EuroQol-5D-5L (EQ-5D-5L) Visual Analogue Scale (VAS)					
MYP	70.53 (18.77)	70.76 (16.71)	0.90 (13.27)	2.62 (-3.44, 8.68)	0.401
Control	71.57 (21.88)	68.43 (21.66)	-3.13 (12.40)		
EuroQol-5D-5L (EQ-5D-5L) Index					
MYP	0.81 (0.11)	0.80 (0.16)	-0.01 (0.11)	-0.00 (-0.05, 0.04)	0.837
Control	0.82 (0.10)	0.82 (0.12)	0.00 (0.07)		
Hospital Anxiety and Depression Scale (HADS) (Anxiety)					
MYP	4.80 (4.13)	3.90 (3.72)	-0.90 (2.87)	-0.10 (-1.22, 1.02)	0.860
Control	3.23 (2.49)	2.93 (2.66)	-0.17 (2.19)		
Hospital Anxiety and Depression Scale (HADS) (Depression)					
MYP	4.57 (3.82)	3.76 (3.52)	-0.90 (3.07)	-0.84 (-2.17, 0.48)	0.218
Control	4.17 (2.90)	4.28 (3.5)	0.17 (2.16)		
Hospital Anxiety and Depression Scale (HADS) (Overall)					
MYP	9.37 (7.45)	7.66 (6.68)	-1.79 (4.97)	-1.04 (-3.16, 1.09)	0.345
Control	7.40 (4.80)	7.17 (5.51)	-0.03 (3.59)		
Patient-Reported Outcomes Measurement Information System (PROMIS™) Sleep Disturbance (SD)					
MYP	45.29 (9.52)	45.80 (8.73)	0.89 (8.60)	2.35 (-1.10, 5.79)	0.188
Control	48.62 (9.48)	46.29 (9.6)	-2.13 (5.76)		
Patient-Reported Outcomes Measurement Information System (PROMIS™) Sleep-Related Impairment (SRI)					
MYP	47.32 (8.78)	45.77 (8.08)	-1.10 (7.62)	-1.77 (-5.50, 1.95)	0.356
Control	44.63 (9.61)	45.92 (10.66)	1.58 (7.66)		

Epworth Sleepiness Scale (ESS)					
MYP	7.03 (3.94)	6.03 (4.40)	-0.90 (2.92)	-0.79 (-2.49, 0.91)	0.367
Control	4.63 (2.92)	4.90 (3.57)	0.38 (3.16)		

Notes:
[*] Week 12 is the end of the intervention period. Mean (standard deviation) values were computed for all patients with complete data at baseline and week 12.
[†] We perform an unadjusted comparison of the change (week 12 – baseline) of each of the primary outcomes between the two study arms (treatment and control).
[‡] A linear regression model was used treatment differences at week 12 for outcomes, adjusting for age, sex, BMI, supplementary oxygen usage, and the baseline value of the specific outcome measure under consideration. Complete case analysis results presented here.

516 **FIGURES**



517 **Figure E1:** Study protocol.



518

519 **Figure E2:** Central themes contributing to improved sense of well-being among yoga

520 participants.



521

522 **Figure E3.** Cough domain score via the Living with Idiopathic Pulmonary Fibrosis scale (L-
523 IPF) (panel A), total score via the Living with Idiopathic Pulmonary Fibrosis scale (L-IPF)
524 (panel B), and cough domain score via the Raghu scale for pulmonary fibrosis (R-Scale-PF)
525 (panel C) from baseline to week 12.